Maxsulin N 100 – Insulin Human (NPH)

What is Maxsulin N?

Maxsulin N is an intermediate-acting human insulin (Isophane/NPH) manufactured by Incepta Pharmaceuticals Ltd. It is used to control blood glucose levels in people with type 1 and type 2 diabetes mellitus, providing a steadier, longer-lasting insulin supply than short-acting insulins.

Generic Name and Composition

Each mL of suspension contains 100 IU of Insulin Human (Isophane/NPH), produced using recombinant DNA technology, identical in structure to naturally occurring human insulin.

Indications

• Type 1 diabetes mellitus (as part of a basal-bolus or premixed regimen)
• Type 2 diabetes mellitus when oral antidiabetic agents are insufficient
• Diabetes management requiring intermediate-duration basal insulin coverage

How It Works — Mechanism of Action

Maxsulin N is a suspension of insulin complexed with protamine, which slows its absorption from the injection site. This delayed absorption gives it an intermediate duration of action, lowering blood glucose by promoting peripheral glucose uptake (especially in skeletal muscle and fat) and inhibiting hepatic glucose production.

Dosage and Administration

• Dosage is individualized by a physician based on blood glucose monitoring, body weight, and treatment goals.
• Administered by subcutaneous injection only — not for intravenous or intramuscular use.
• Gently roll the vial between your palms (do not shake vigorously) until the suspension is uniformly white and cloudy before each use.
• Rotate injection sites (abdomen, thigh, upper arm, buttock) to reduce the risk of lipodystrophy.
• Often used in combination with a short-acting insulin or oral antidiabetic agents as directed by a physician.
• Do not change the brand, type, or dose of insulin without medical supervision.

Side Effects

Common: Hypoglycemia, injection site reactions (redness, swelling, itching), lipodystrophy with repeated injection at the same site.

Uncommon: Generalized allergic reactions (rash, urticaria), transient visual disturbances at the start of therapy, peripheral edema.

Rare: Severe systemic hypersensitivity reactions, anaphylaxis.

Drug Interactions

Detailed, severity-graded drug interaction data specific to Maxsulin N is not reliably available from the manufacturer's published literature. As a general class precaution with human insulins: medicines such as oral antidiabetics, ACE inhibitors, MAOIs, and alcohol may enhance the blood-glucose-lowering effect, while corticosteroids, thyroid hormones, oral contraceptives, and thiazide diuretics may reduce it. Beta-blockers may mask the warning signs of hypoglycemia. Always inform your physician or pharmacist of all medicines you are taking.

Contraindications

• Known hypersensitivity to insulin human or any excipient in the formulation
• Episodes of hypoglycemia

Pregnancy and Lactation

Insulin is a standard treatment for diabetes during pregnancy and breastfeeding, as it does not cross into breast milk in clinically significant amounts. Dose requirements often change during pregnancy and lactation — use only under close medical supervision.

Precautions and Warnings

• Never share insulin vials, pens, or needles between patients, even if the needle is changed.
• Monitor blood glucose regularly, especially when changing dose, diet, activity level, or during illness.
• Use caution in patients with renal or hepatic impairment, as insulin requirements may be reduced.
• Carry a fast-acting source of sugar at all times in case of hypoglycemia.
• Inform your doctor before starting any new medication, including over-the-counter products.

Overdose

Overdose can cause hypoglycemia, with symptoms ranging from sweating, palpitations, tremor, and hunger to confusion, seizures, and loss of consciousness in severe cases. Mild episodes can be managed with oral glucose or sugar; severe or unconscious episodes require immediate medical attention, including intravenous glucose or glucagon administration.

Storage Instructions

• Store unopened vials in a refrigerator at 2–8°C. Do not freeze.
• Once in use, the vial may be kept below 25°C (away from direct heat and light) for up to 6 weeks, or below 30°C for up to 4 weeks, then discarded.
• Keep out of reach of children.
• Do not use if the suspension appears clumped, discolored, or contains visible particles after rolling.

Frequently Asked Questions

Q1: How is Maxsulin N different from regular short-acting insulin?
Maxsulin N is an intermediate-acting (NPH) insulin with a slower onset and longer duration, used to provide steady background insulin coverage rather than rapid post-meal control.

Q2: Can I mix Maxsulin N with other insulins in the same syringe?
Some intermediate and short-acting insulins can be mixed under medical guidance, but this should only be done as specifically instructed by your physician.

Q3: Why does Maxsulin N look cloudy while some other insulins look clear?
Maxsulin N is a suspension because the insulin is bound to protamine to delay its absorption — this is normal and is why the vial must be rolled gently before each use.

Q4: How is Maxsulin N different from Maxsulin 30/70 or Vibrenta?
Maxsulin N is a pure intermediate-acting (NPH) insulin, Maxsulin 30/70 is a premixed combination of short- and intermediate-acting insulin, and Vibrenta (insulin glargine) is a long-acting basal analogue with a smoother, near-peakless profile. Your physician will choose the option that best fits your treatment plan.

Medical Disclaimer

This product is available by prescription only (Rx). The information provided is for educational purposes and does not replace professional medical advice. Always consult a registered physician before starting, stopping, or changing any insulin therapy. DiabetesStore.com.bd is a licensed online pharmacy in Bangladesh.